Product Description
JW-200 was developed by Jupiter Wellness in order to treat patients with actinic keratosis. (Sourcd from: https://www.sec.gov/Archives/edgar/data/1760903/000149315221024981/ex99-1.htm)
Mechanisms of Action: COX2 Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Jupiter Wellness
Company Location: JUPITER FL 33458
Company CEO: Brian S. John
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Keratosis, Actinic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/18/2022 |
News Article |
Jupiter Wellness Completes Enrollment in Double-Blind Placebo-Controlled Clinical Trial of JW-200 for the Treatment of Actinic Keratosis |
|
10/07/2021 |
News Article |
Jupiter Wellness Provides Shareholder Update on Multiple Clinical & Commercial Milestones |
|
04/29/2021 |
News Article |
Jupiter Wellness Advances Clinical Pipeline of CBD-Based Topical Treatments |